Lv11
40 积分 2024-10-24 加入
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
4小时前
已完结
Allodynia (skin tenderness) associated with semaglutide: A case series
12天前
已关闭
Allodynia (skin tenderness) associated with semaglutide: A case series
12天前
已关闭
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
12天前
已完结
Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials
26天前
已完结
[Experts consensus on diagnosis and treatment of Epstein-Barr virus infection-related diseases in children]
28天前
已完结
RNA Interference With Zilebesiran for Mild to Moderate Hypertension
1个月前
已完结
The Impact of the Rate of Weight Loss on Body Composition and Metabolism
1个月前
已完结
Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis
1个月前
已完结
Contrasting approaches for addressing non-adherence in randomized controlled trials: An illustration from the REFLUX trial
6个月前
已完结
皖公网安备34019202002308
